Eli Lilly and Company has announced a significant debt offering, issuing multiple series of notes amounting to a total of approximately $6.71 billion in net proceeds. The offering includes $750 million in Floating Rate Notes due 2028, $1 billion in 4.000% Notes due 2028, $750 million in 4.250% Notes due 2031, $1 billion in 4.550% Notes due 2032, $1.25 billion in 4.900% Notes due 2035, $1 billion in 5.550% Notes due 2055, and $1 billion in 5.650% Notes due 2065. The maturity dates for these notes range from October 15, 2028, to October 15, 2065, with interest rates varying from 4.000% to 5.650% per annum, payable semi-annually. The offering was registered under a Registration Statement on Form S-3.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-184093), on August 20, 2025, and is solely responsible for the information contained therein.